# Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers

> **NCT01848002** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 24 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Congenital FXIII Deficiency
- Healthy

## Interventions

- **DRUG:** catridecacog
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01848002
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2003-08
- **Final completion:** 2003-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848002, "Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01848002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*